Sign inCreate account

Report workspace tools

NCT01587924COMPLETEDanonymous

A Four-week, Phase IIa, Randomized, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Switching Subjects From a Stable Dose of Recombinant Human Erythropoietin to GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease

Sponsor

Source record

GlaxoSmithKline

Phase

Source record

Phase IIa

Modality

AI-normalized

small molecule

Target

AI-normalized

GSK1278863 for anemia in hemodialysis-dependent patients

Indication / condition

AI-normalized

Anaemia

Intervention

Source record

GSK1278863, rhEPO

Source & freshness

Source record

NCT ID

NCT01587924

Original source

ClinicalTrials.gov

Source last updated

Nov 14, 2017

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01587924

Title

A Four-week, Phase IIa, Randomized, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Switching Subjects From a Stable Dose of Recombinant Human Erythropoietin to GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease

Sponsor

GlaxoSmithKline

Status

COMPLETED

Phase

Phase IIa

Condition raw

Anaemia

Condition normalized

Anaemia

Modality raw

Anaemia

Modality normalized

small molecule

Target raw

GSK1278863 for anemia in hemodialysis-dependent patients

Target normalized

GSK1278863 for anemia in hemodialysis-dependent patients

Interventions

GSK1278863, rhEPO

Public preview

Source record

This clinical trial evaluated the safety, efficacy, and pharmacokinetics of GSK1278863, a novel treatment for anemia associated with chronic kidney disease, in hemodialysis-dependent subjects. The study involved switching patients from a stable dose of recombinant human erythropoietin (rhEPO) to GSK1278863 over a four-week period.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Four-week, Phase IIa, Randomized, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Switching Subjects From a Stable Dose of Recombinant Human Erythropoietin to GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01587924

Status

COMPLETED

Phase

Phase IIa

Sponsor

GlaxoSmithKline

Executive brief

Investment-Ready Snapshot

This clinical trial evaluated the safety, efficacy, and pharmacokinetics of GSK1278863, a novel treatment for anemia associated with chronic kidney disease, in hemodialysis-dependent subjects. The study involved switching patients from a stable dose of recombinant human erythropoietin (rhEPO) to GSK1278863 over a four-week period.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedNov 14, 2017
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01587924

Indication

Anaemia

Modality

small molecule

Target

GSK1278863 for anemia in hemodialysis-dependent patients

Intervention

GSK1278863, rhEPO

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.